All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Relacorilant Combo Improves PFS, Trends Toward Superior OS in Platinum-Resistant Ovarian Cancer

June 2nd 2025

Relacorilant plus nab-paclitaxel showed meaningful PFS and OS gains, offering a potential new option for patients with platinum-resistant ovarian cancer.

Dostarlimab Plus Chemo With Maintenance Niraparib Generates Modest PFS Boost in Advanced Ovarian Cancer

June 2nd 2025

Dostarlimab/chemotherapy plus maintenance niraparib showed clinically modest PFS improvements vs niraparib alone in newly diagnosed advanced ovarian cancer.

EBC-129 Is Active and Safe in Heavily Pretreated mPDAC

June 2nd 2025

EBC-129 monotherapy was active, generated responses, and had a manageable safety profile in heavily pretreated metastatic pancreatic ductal adenocarcinoma.

KEYNOTE-A18 Data Support Pembrolizumab Plus CCRT as New SOC in High-Risk Cervical Cancer

June 2nd 2025

Pembrolizumab plus CCRT showcases sustained survival benefits in high-risk locally advanced cervical cancer.

Perioperative Nivolumab Sustains EFS Advantage in Resectable NSCLC, With Enriched Benefit in ctDNA–, pCR Responders

June 2nd 2025

Neoadjuvant chemotherapy and nivolumab and adjuvant nivolumab prolonged EFS vs placebo in patients with resectable NSCLC in follow-up from CheckMate-77T.

Higher Pretreatment HER2 Amplicon mRNA Signature Predicts Improved Outcomes With Trastuzumab Deruxtecan in Metastatic Breast Cancer

June 2nd 2025

Patients with metastatic breast cancer with higher HER2 amplicon mRNA signatures prior to T-DXd therapy had better outcomes vs those with lower signatures.

Frontline Ficerafusp Alfa Plus Pembrolizumab Shows Promise in HPV-Negative HNSCC

June 2nd 2025

Ficerafusp alfa plus pembrolizumab elicited deep responses in HPV-negative recurrent or metastatic head and neck cancer.

Cabozantinib Displays Activity as Combination Component and Monotherapy in Second-Line Advanced RCC

June 2nd 2025

Cabozantinib plus atezolizumab or cabozantinib alone was effective regardless of prior immunotherapy or TKI treatment in second-line advanced RCC.

LB2102 CAR T-Cell Therapy Is Well Tolerated, Yields Disease Control in R/R SCLC and LCNEC

June 2nd 2025

The DLL3-directed CAR T-cell therapy LB2102 was safe with preliminary antitumor activity in small cell lung cancer and large cell neuroendocrine carcinoma.

Neoadjuvant Alectinib Yields Responses in Late-Stage, Potentially Resectable ALK+ NSCLC

June 2nd 2025

Neoadjuvant alectinib produced major pathologic responses, and it was tolerable and feasible in potentially resectable, stage III, ALK-positive NSCLC.

Lutetium Lu 177 Vipivotide Tetraxetan Generates rPFS Improvement in PSMA+ mHSPC

June 2nd 2025

Lutetium Lu 177 vipivotide tetraxetan plus hormone therapy yielded rPFS and OS benefits vs hormone therapy alone in patients with PSMA-positive mHSPC.

Addition of Toripalimab to Induction Improves PFS in Nonresectable NSCLC

June 2nd 2025

Adding induction toripalimab to chemotherapy followed by definitive chemoradiotherapy and consolidation therapy reduced risk for disease progression by 74%.

Rusfertide Shines as New Treatment Option in Polycythemia Vera

June 2nd 2025

In the VERIFY study, rusfertide significantly improved clinical responses vs placebo in polycythemia vera, offering a potential new therapy.

FDA Grants Priority Review to Ziftomenib in NPM1-Mutant R/R AML

June 2nd 2025

The FDA has granted priority review to ziftomenib for relapsed/refractory acute myeloid leukemia harboring an NPM1 mutation.

First-Line T-DXd Plus Pertuzumab Yields PFS Benefit in HER2+ Advanced Breast Cancer

June 2nd 2025

Trastuzumab deruxtecan plus pertuzumab produced a statistically significant PFS improvement in frontline HER2-positive advanced breast cancer.

Belantamab Mafodotin Triplet Improves PFS, Responses in R/R Myeloma With High-Risk Cytogenetics

June 2nd 2025

Belantamab mafodotin plus Pd improved PFS and response rates in patients with relapsed/refractory multiple myeloma with high-risk cytogenetics.

Long-Term Data Demonstrate Sustained DFS Benefit With Adjuvant Pembrolizumab in ccRCC

June 1st 2025

Adjuvant pembrolizumab showed maintained OS and DFS vs placebo in patients with ccRCC at the 5-year analysis.

Talquetamab Is Safe and Effective in R/R Multiple Myeloma

June 1st 2025

Talquetamab led to durable responses and promising survival outcomes in patients with relapsed/refractory multiple myeloma.

Nivolumab/Ipilimumab Maintains Prolonged Survival and Generates Durable Responses in Advanced RCC

June 1st 2025

First-line nivolumab/ipilimumab demonstrated sustained survival signals and responses vs sunitinib in previously untreated advanced RCC.

Mitomycin/BCG Combo Could Alleviate BCG Shortage Concerns for NMIBC

June 1st 2025

BCG plus mitomycin may represent good alternative to BCG alone in NMIBC.